Study Title
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies (NCT01461538)

Trial Description
This is an open-label, multicenter, phase II clinical trial to evaluate the antitumor activity of the antibody-drug conjugate (ADC) brentuximab vedotin (also known as SGN-035) as a single agent in patients with CD30-positive nonlymphomatous malignancies.

This trial is sponsored by Seattle Genetics. [1]

Study Data

  • Condition: Nonlymphomatous Malignancies
  • Interventions:
  • Phase: II
  • Enrollment: 84
  • Start: October 2011
  • Completion: December 2014
  • Last verified: May 2015

Study Schematic 

(Coming soon)

Last Editorial review: July 2, 2015
Information based on (NIH/NCI) and other sources.